A prospective phase II trial of simultaneous modulated accelerated radiotherapy (SMART) combined chemotherapy in patients with stage III non-small cell lung cancer

A prospective phase II trial of simultaneous modulated accelerated radiotherapy (SMART) combined Carboplatin/Paclitaxel in patients with stage IIIA/IIIB non-small cell lung cancer

Status

Recruiting

Phases

Phase 2

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPC-15006113

Enrollment

Unknown

Registered

2015-03-17

Start date

2015-03-10

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

1:SMART combined chemotherapy

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. There are definite pathological diagnosis; 2. Stage with IIIA/IIIB; 3. ECOG 0-1; 4. Age 18-75 years old; 5. Life expectancy six months; 6. Unaccompanied other cancer; 7. Adequate bone marrow, liver and kidney function; 8. Lung function FEV1>70%; 9. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. History of aggressive tumor, expect for at least two years of disease-free survival; 2. Previously had received radiation therapy, and the two radiation fields have a overlap; 3. With serious medicine disease; 4. Lactating women.

Design outcomes

Primary

Measure	Time frame
survival rate;	—

Countries

China

Contacts

Public ContactLisheng Huang

364965305@qq.com+86 13750483123

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026